nach oben

CNS Drugs

Erschienen in:

01.08.2001 | Review Article

Adverse Effects of Antiepileptic Drugs on Bone Structure

Epidemiology, Mechanisms and Therapeutic Implications

verfasst von: Dr Alison M. Pack, Martha J. Morrell

Erschienen in: CNS Drugs | Ausgabe 8/2001

Einloggen, um Zugang zu erhalten

Abstract

Antiepileptic drugs (AEDs) were first associated with disorders of bone in both adults and children in the late 1960s. The most severe manifestations of these disorders are osteopenia/osteoporosis, osteomalacia and fractures. Bone disease has been described in several groups of patients receiving AEDs. Groups identified as being more vulnerable to AED-associated bone disease include institutionalised patients, postmenopausal women, older men and children.

Radiological and histological evidence of bone disease is found in patients taking AEDs. Numerous biochemical abnormalities of bone metabolism have also been described. The severity of bone and biochemical abnormalities is thought to correlate with the duration of AED exposure and the number of AEDs used. In monotherapy, the AEDs most commonly associated with altered bone metabolism are phenytoin, primidone and phenobarbital (phenobarbitone). To date there have been no reports of altered bone metabolism in individuals receiving the newer anticonvulsants (specifically lamotrigine, topiramate, vigabatrin and gabapentin).

The mechanisms of AED-associated bone disease are not clearly elucidated; however, several theories have been proposed to explain the link. No definitive guidelines for evaluation or treatment have yet been determined.

Jaglal SB, Kreiger N, Darlington GA. Lifetime occupational physical activity and risk of hip fracture in women. Ann Epidemiol 1995; 5(4): 321–4PubMedCrossRef

Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332(12): 767–73PubMedCrossRef

Desai KB, Ribbans WJ, Taylor GJ. Incidence of five common fractures in an institutionalized epileptic population. Injury 1996; 27(2): 97–100PubMedCrossRef

Vestergaard P, Tigaran S, Rejnmark L, et al. Fracture risk is increased in epilepsy. Acta Neurol Scand 1999; 99: 269–75PubMedCrossRef

Kruse R. Osteopathien bei antiepileptischer Langzeittherapie. Monatasschr Kinderheilkd 1968; 116: 378–81

Dent CE, Richens A, Rowe DFJ, et al. Osteomalacia with long-term anticonvulsant therapy in epilepsy. BMJ 1970; 4: 69–72PubMedCrossRef

Richens A, Rowe DFJ. Disturbance of calcium metabolism by anticonvulsant drugs. BMJ 1970; 4: 73–6PubMedCrossRef

Hunter J, Maxwell JD, Stewart DA, et al. Altered calcium metabolism in epileptic children on anticonvulsants. BMJ 1971; 4(781): 202–4PubMedCrossRef

Hoikka V, Savolainen K, Esko M, et al. Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. Acta Neurol Scan 1981; 64: 122–31CrossRef

10.

Nilsson OS, Lindholm TS, Elmstedt E, et al. Fracture incidence and bone disease in epileptics receiving long-term anticonvulsant drug treatment. Arch Orothop Trauma Surg 1986; 105(3): 146–9CrossRef

11.

Ross PD, He Y-F, Davis JW, et al. Normal ranges for bone loss rates. Bone Miner 1994; 26: 169–80PubMedCrossRef

12.

Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case controlled study. Seizure 1999; 8(6): 339–42PubMedCrossRef

13.

Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995; 127: 256–62PubMedCrossRef

14.

Livingston S, Berman W, Pauli LL. Anticonvulsant drugs and vitamin D metabolism. J Am Med Assoc 1973; 24: 1634–5CrossRef

15.

Hahn TJ, Scharp CR, Richardson CA. Interaction of diphenyl-hydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro. J Clin Invest 1978; 62: 406–14PubMedCrossRef

16.

Mimaki T, Walson PD, Haussler MR. Anticonvulsant therapy and vitamin D metabolism: evidence for different mechanisms for phenytoin and Phenobarbital. Pediatr Pharmacol 1980; 1: 105–12

17.

Chung S, Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 1994; 16: 382–5PubMedCrossRef

18.

Mosekilde L, Melsen F. Anticonvulsant osteomalacia determined by quantitative analysis of bone changes. Acta Med Scand 1976; 199: 349–55PubMedCrossRef

19.

Mosekilde L, Melsen F, Christensen MS, et al. Effect of long-term vitamin D₂ treatment on bone morphometry and biochemical values in anticonvulsant osteomalacia. Acta Med Scand 1977; 210: 303–7

20.

Hoikka V, Savolainen KE, Alhava EM, et al. Anticonvulsant osteomalacia in epileptic outpatients. Ann Clin Res 1982; 14: 129–32PubMed

21.

Sotaniemi EA, Hakkarainen HK, Puranen JA, et al. Radiologic bone changes and hypocalcemia with anticonvulsant therapy in epilepsy. Ann Intern Med 1972; 77: 389–94PubMed

22.

Christiansen C, Rodbro P, Lund M. Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. BMJ 1973; 4: 695–701PubMedCrossRef

23.

Weinstein RS, Bryce GF, Sappington LJ, et al. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 1984; 58: 1003–9PubMedCrossRef

24.

Fischer MH, Adkins Jr WN, Liebl BH, et al. Bone status in nonambulant epileptic institutionalized youth. Clin Pediatr 1988; 10: 499–505CrossRef

25.

LeBlanc AD, Evans HJ, Marsh C, et al. Precision of dual photon absorptiometry measurements. J Nucl Med 1986 Aug; 27(8): 1362–5PubMed

26.

Timperlake RW, Cook SD, Thomas KA, et al. Effects of anticonvulsant drug therapy on bone mineral density in a pediatric population. J Pediatr Orthop 1988; 8: 467–70PubMedCrossRef

27.

Valimaki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on anti-epileptic drugs. J Bone Miner Res 1994; 9: 631–7PubMedCrossRef

28.

Seale CG, Morrell MJ, Marcus R, et al. Bone mineral density in AED treated women with epilepsy [abstract]. Epilepsia 1999; 40 Suppl. 7: H.01

29.

Seale CG, Morrell MJ, Shane E, et al. Bone health in women with epilepsy [abstract]. Epilepsia 2000; 41 Suppl. 7: 3.096

30.

Pluskiewicz W, Nowakowska J. Bone status after long-term anticonvulsant therapy in epileptic patients: evaluation using quantitative ultrasound of calcaneus and phalanges. Ultrasound Med Biol 1997; 23(4): 553–8PubMedCrossRef

31.

Hahn TJ, Hendin B A, Scharp CR. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 1972; 287(18): 900–4PubMedCrossRef

32.

Bouillon R, Reynaert J, Claes JH, et al. The effect of anticonvulsant therapy on serum levels of 25-hydroxyvitamin D, calcium, and parathyroid hormone. J Clin Endocrinol Metab 1975; 41: 1130PubMedCrossRef

33.

Berry JL, Mawer EB, Walker DA, et al. Effect of antiepileptic drug therapy and exposure to sunlight on vitamin D status in institutionalized patients. In: Oxley J, Janz D, Meinardi H, editors. Antiepileptic therapy: chronic toxicity of antiepileptic drugs, New York: Raven Press, 1983: 185–92

34.

Gough H, Goggin T, Bissessar A, et al. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in outpatients with epilepsy. Q J Med 1986; 230: 569–77

35.

O’Hare JA, Duggan B, O’Driscoll D, et al. Biochemical evidence for osteomalacia with carbamazepine therapy. Acta Neurol Scand 1980; 62: 282–6PubMedCrossRef

36.

Bogliun G, Beghi E, Crespi V, et al. Anticonvulsant drugs and bone metabolism. Acta Neurol Scand 1986; 74: 284–8PubMedCrossRef

37.

Brown AJ, Dusso A, Slatopolsky E. Vitamin D. AJP-Renal Physiol 1999; 277(2): F157–F75

38.

Hoikka V, Alhava EM, Karjalainen P, et al. Carbamazepine and bone mineral metabolism. Acta Neurol Scand 1984; 69: 77–80CrossRef

39.

Davie MW, Emberson CE, Lawson DEM, et al. Low plasma 25-hydroxyvitamin D and serum calcium in institutionalized epileptic subjects: associated risk factors, consequences and response to treatment with vitamin D. Q J Med 1983; 205: 79–91

40.

Stamp TCB, Round JM, Haddad JG. Plasma levels and therapeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs. BMJ 1972; 4: 9–12PubMedCrossRef

41.

Tjellesen L, Christiansen C. Serum vitamin D metabolites in epileptic patients treated with 2 different anti-convulsants. Acta Neurol Scand 1982; 66: 335–41PubMedCrossRef

42.

Tjellesen L, Nilas L, Christiansen C. Does carbamazepine cause disturbances in calcium metabolism in epileptic patients? Acta Neurol Scand 1983; 68: 13–9PubMedCrossRef

43.

Tolman KG, Jubiz W, Sannella JJ, et al. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics 1975; 56: 45–51PubMed

44.

Skillen AW, Peirides AM. Serum gamma glutamyl transferase and alkaline phosphatase activities in epileptics receiving anticonvulsant therapy. Clin Chim Acta 1976; 72: 245–51PubMedCrossRef

45.

Okesina AB, Donaldson D, Lascelles PT. Isoenzymes of alkaline phosphatase in epileptic patients receiving carbamazepine monotherapy. J Clin Pathol 1991; 44: 480–2PubMedCrossRef

46.

Garnero P, Delmas PD. Biochemical markers of bone turnover. Endocrinol Metab Clin North Am 1998; 27(2): 303–23PubMedCrossRef

47.

TakeshitaN, SeinoY, Ishida H, et al. Increased circulating levels of gamma-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy. Calcif Tissue Int 1989; 44: 80–5CrossRef

48.

Verrotti A, Greco R, Morgese G, et al. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000; 47: 385–8PubMedCrossRef

49.

Nielsen HE, Melsen F, Lund B, et al. Bone histomorphometry, vitamin D metabolites and calcium phosphate metabolism in anticonvulsant treatment with carbamazepine. Calcif Tissue Int 1983; 35 Suppl. A58: 224

50.

Tjellesen L, Gotfredsen A, Christiansen C. Effect of vitamin D₂ and D₃ on bone-mineral content in carbamazepine-treated epileptic patients. Acta Neurol Scand 1983; 68: 424–8PubMedCrossRef

51.

Gough H, Bissesar A, Goggin T, et al. Factors associated with the biochemical changes in vitamin D and calcium metabolism in institutionalized patients with epilepsy. Ir J Med Sci 1986; 155(6): 181–9PubMedCrossRef

52.

Perucca E. Clinical implications of hepatic microsomal enzyme induction by anti-epileptic drugs. Pharmacol Ther 1987; 33: 130–44CrossRef

53.

Tjellesen L, Hummer L, Christiansen C, et al. Different metabolism on vitamin D₂/D₃ in epileptic patients treated with phenobarbitone/phenytoin. Bone 1986; 7: 337–42PubMedCrossRef

54.

Collins N, Maher J, Cole M, et al. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 1991; 78: 113–22PubMed

55.

Hartwell D, Tjellesen L, Christiansen C, et al. Metabolism of vitamin D₂ and vitamin D₃ in patients on anticonvulsant therapy. Acta Neurol Scand 1989; 79: 487–92PubMedCrossRef

56.

Koch HV, Kratf D, von Herrath D. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia 1972; 13: 829–41PubMedCrossRef

57.

Hahn TJ, Hendin BA, Scharp CR, et al. Serum 25-hydroxy calciferol levels and bone mass in children on chronic anti-epileptic therapy. N Engl J Med 1975; 292: 550–4CrossRef

58.

Vernillo AT, Rifkin BR, Hauschka PV. Phenytoin affects osteo-blastic secretion form osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone 1990; 11: 309–12PubMedCrossRef

59.

Kruse K, Suss A, Busse M, et al. Monomeric serum calcitonin and bone turnover during anticonvulsant treatment and in congenital hypothyroidism. J Pediatr 1987; 111: 57–63PubMedCrossRef

Titel: Adverse Effects of Antiepileptic Drugs on Bone Structure
Epidemiology, Mechanisms and Therapeutic Implications
verfasst von: Dr Alison M. Pack
Martha J. Morrell
Publikationsdatum: 01.08.2001
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 8/2001
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200115080-00006

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2001

When Should Triptans be Taken During a Migraine Attack?

Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation

CNS Involvement in Primary Sjögren’s Syndrome

Do Statins Afford Neuroprotection in Patients with Cerebral Ischaemia and Stroke?

Venlafaxine Extended-Release